NanoMarkets, a leading industry
consultancy based here, today announced the release of two white papers that
address the role of nanotechnology in drug discovery and drug delivery. The
papers are available for immediate download from the firm's web site,
http://www.nanomarkets.net.
Background:
As the pharmaceutical industry matures, meeting Wall Street's aggressive
growth expectations becomes increasingly difficult. Many companies will
continue to grow via merger and acquisition activity and through internal
development of high-value compounds. Nonetheless, over the next decade,
several blockbuster drugs will go off patent, resulting in an estimated loss
of $30-$40 billion in annual product revenues as generic drugs enter the
market. This change is accelerating the industry's constant need to "build
the pipeline" of new compounds, and to rapidly enter new markets. Naturally,
these trends are creating new challenges and opportunities in drug discovery.
It is also a significant driver of change in Drug Delivery Systems (DDS),
which are increasingly being used to alleviate some of the industry's concerns
by extending product and patent lifecycles, creating New Chemical Entities
(NCE's) via reformulation of existing and/or orphaned compounds, and
subsequent creation of value for shareholders and consumers. When you add in
the massive amount of nanotechnology and pharmaceutical R&D funding now
available worldwide, the drug delivery industry is evolving rapidly and is
nearly unrecognizable from its humble beginnings in the 1960's. This $40-
billion market has seen double-digit growth for the past two decades, and the
industry's success has spawned intense competition.
NanoMarkets believes that important opportunities exist at the
intersection of nanotechnology and traditional pharmaceutical R&D, though much
uncertainty remains on how this will affect the industry.
About the Papers:
The first paper titled, "Factors Pushing the Growth of Nano-Enabled Drug
Discovery," examines how nanotechnology can enhance the drug discovery process
and discusses how various economic, technical, financial and societal trends
are pointing to real opportunities. Although at an embryonic stage of
development, nano-enabled drugs are already bringing clinical benefits to
thousands of patients. The second paper titled, "The Nano-Enabled Drug
Delivery Systems Market," discusses the contributions that nanotechnology is
making to the pharmaceutical industry in the areas of solubility enhancements,
reduced development costs, greater targeting availability and consumer-
friendly products. The paper goes on to examine market competition,
challenges and trends pointing toward a greater need for nanotech based
solutions.
About NanoMarkets' Research Program:
NanoMarkets is currently conducting an extensive examination of the
opportunities for the application of nanotechnology in the pharmaceutical
sector. The first deliverables will be available early in the first quarter
of 2005 and will address the major drivers, restraints and challenges for
current and emerging applications of nanotechnology in drug discovery and
drug-delivery markets. NanoMarkets is making the reports available at a
discounted rate through the end of 2004. For additional information about
these reports, you may contact Robert Nolan at sales@nanomarkets.net or
(571) 434-7520 or visit http://www.nanomarkets.net to learn more.
About NanoMarkets:
NanoMarkets analyzes the impact of nanotechnology on both established and
emerging markets with a focus on the realms of communications, IT,
semiconductors, bio-medical and energy. The firm provides market research
reports, customized industry analyses and general market commentary for
companies looking to capitalize on nanotechnology-based opportunities.
